Vivek Subbiah, MD, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, kicks off his new series on Healthcare Unfiltered, “VIVEK’S TAKES,” in which he will provide his expert feedback on the importance and lasting effects of research presented at the top medical conferences in the world.
In response to the 2024 ASCO Annual Meeting, Dr. Subbiah shares the themes he sees being developed in multiple cancer subspecialties, including breast, lung, and pancreatic, as well as the research-driven benefits of receiving care on clinical trials and early palliative care via telemedicine.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
